| Cadila Healthcare has received phase-I clinical trial permission from the DCGI for ZYOG1, a novel GLP-1 agonist, designed and developed at the company's research centre using a unique platform technology. ZYOG1 is a novel, oral anti-diabetic molecule. |
No comments:
Post a Comment